Arielle Davidson, Christina Inteso, Nolan Rossman, Toni Larson, Kathryn Dudzinski
{"title":"GLP-1激动剂与其他体重管理药物在肥胖和超重患者中的疗效","authors":"Arielle Davidson, Christina Inteso, Nolan Rossman, Toni Larson, Kathryn Dudzinski","doi":"10.1016/j.japhpi.2025.100046","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Glucagon-like peptide-1 (GLP-1) agonists are efficacious for weight management; however, there are barriers that prevent access. Although studies have shown the efficacy of individual treatments, there is a lack of evidence that compares different classes of weight management medications with each other.</div></div><div><h3>Objective</h3><div>This study aimed to compare the efficacy of GLP-1 agonists with other classes of weight management medications.</div></div><div><h3>Methods</h3><div>This retrospective chart review included patients prescribed a weight management medication by a primary care pharmacist at Corewell Health between June 1, 2022, and June 1, 2023. Patients were assigned to (1) the GLP-1 agonist group or (2) the non-GLP-1 agonist group. The primary outcome was the percentage of patients who reached ≥ 5% weight loss at the end of the treatment course. The secondary outcomes include the percentage of patients who reached ≥ 10% weight loss and ≥ 15% weight loss at the end of the treatment course and average change in body mass index (BMI) at the end of the treatment course.</div></div><div><h3>Results</h3><div>A higher number of patients in the GLP-1 agonist group achieved the primary end point of ≥ 5% weight loss compared with the non-GLP-1 agonist group (29 patients [50.9%] vs. 17 patients [30.9%], <em>P</em> = 0.0318). A logistic model was done, which showed that, when accounting for medication duration, the number of patients in the GLP-1 agonist group who reached the primary end point was not statistically significant compared with the non-GLP-1 agonist group with a <em>P</em> value of 0.0772. There was not a statistically significant difference in the number of patients who achieved ≥ 10% and ≥ 15% weight loss between groups, whereas BMI change was statistically significantly greater in the GLP-1 agonist group.</div></div><div><h3>Conclusion</h3><div>A higher percentage of patients in the GLP-1 agonist group reached ≥ 5% weight loss as compared to patients in the non-GLP-1 agonist group, without regard to medication duration.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 3","pages":"Article 100046"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of GLP-1 agonists vs. other weight management medications in obese and overweight patients\",\"authors\":\"Arielle Davidson, Christina Inteso, Nolan Rossman, Toni Larson, Kathryn Dudzinski\",\"doi\":\"10.1016/j.japhpi.2025.100046\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Glucagon-like peptide-1 (GLP-1) agonists are efficacious for weight management; however, there are barriers that prevent access. Although studies have shown the efficacy of individual treatments, there is a lack of evidence that compares different classes of weight management medications with each other.</div></div><div><h3>Objective</h3><div>This study aimed to compare the efficacy of GLP-1 agonists with other classes of weight management medications.</div></div><div><h3>Methods</h3><div>This retrospective chart review included patients prescribed a weight management medication by a primary care pharmacist at Corewell Health between June 1, 2022, and June 1, 2023. Patients were assigned to (1) the GLP-1 agonist group or (2) the non-GLP-1 agonist group. The primary outcome was the percentage of patients who reached ≥ 5% weight loss at the end of the treatment course. The secondary outcomes include the percentage of patients who reached ≥ 10% weight loss and ≥ 15% weight loss at the end of the treatment course and average change in body mass index (BMI) at the end of the treatment course.</div></div><div><h3>Results</h3><div>A higher number of patients in the GLP-1 agonist group achieved the primary end point of ≥ 5% weight loss compared with the non-GLP-1 agonist group (29 patients [50.9%] vs. 17 patients [30.9%], <em>P</em> = 0.0318). A logistic model was done, which showed that, when accounting for medication duration, the number of patients in the GLP-1 agonist group who reached the primary end point was not statistically significant compared with the non-GLP-1 agonist group with a <em>P</em> value of 0.0772. There was not a statistically significant difference in the number of patients who achieved ≥ 10% and ≥ 15% weight loss between groups, whereas BMI change was statistically significantly greater in the GLP-1 agonist group.</div></div><div><h3>Conclusion</h3><div>A higher percentage of patients in the GLP-1 agonist group reached ≥ 5% weight loss as compared to patients in the non-GLP-1 agonist group, without regard to medication duration.</div></div>\",\"PeriodicalId\":100737,\"journal\":{\"name\":\"JAPhA Practice Innovations\",\"volume\":\"2 3\",\"pages\":\"Article 100046\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAPhA Practice Innovations\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949969025000211\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAPhA Practice Innovations","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949969025000211","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Efficacy of GLP-1 agonists vs. other weight management medications in obese and overweight patients
Background
Glucagon-like peptide-1 (GLP-1) agonists are efficacious for weight management; however, there are barriers that prevent access. Although studies have shown the efficacy of individual treatments, there is a lack of evidence that compares different classes of weight management medications with each other.
Objective
This study aimed to compare the efficacy of GLP-1 agonists with other classes of weight management medications.
Methods
This retrospective chart review included patients prescribed a weight management medication by a primary care pharmacist at Corewell Health between June 1, 2022, and June 1, 2023. Patients were assigned to (1) the GLP-1 agonist group or (2) the non-GLP-1 agonist group. The primary outcome was the percentage of patients who reached ≥ 5% weight loss at the end of the treatment course. The secondary outcomes include the percentage of patients who reached ≥ 10% weight loss and ≥ 15% weight loss at the end of the treatment course and average change in body mass index (BMI) at the end of the treatment course.
Results
A higher number of patients in the GLP-1 agonist group achieved the primary end point of ≥ 5% weight loss compared with the non-GLP-1 agonist group (29 patients [50.9%] vs. 17 patients [30.9%], P = 0.0318). A logistic model was done, which showed that, when accounting for medication duration, the number of patients in the GLP-1 agonist group who reached the primary end point was not statistically significant compared with the non-GLP-1 agonist group with a P value of 0.0772. There was not a statistically significant difference in the number of patients who achieved ≥ 10% and ≥ 15% weight loss between groups, whereas BMI change was statistically significantly greater in the GLP-1 agonist group.
Conclusion
A higher percentage of patients in the GLP-1 agonist group reached ≥ 5% weight loss as compared to patients in the non-GLP-1 agonist group, without regard to medication duration.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
